Previous close | 50.58 |
Open | 50.82 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 50.26 - 50.82 |
52-week range | 33.27 - 54.90 |
Volume | |
Avg. volume | 236,987 |
Market cap | N/A |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 30 July 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 38.30 |
Pfizer had a surprise beat in its COVID portfolio despite dim forecasts, but the company is still not feeling the love in its stock.
Pfizer (PFE) shares tick up in pre-market trading — continuing into the green after the market open — after the pharmaceutical giant raised its full-year profit outlook and topped first-quarter earnings estimates on the top and bottom lines. Yahoo Finance Health Reporter Anjalee Khemlani joins The Morning Brief to discuss Pfizer's outlook on its future product pipeline. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
NEW YORK, May 01, 2024--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted(3) diluted EPS guidance while maintaining all other components of its 2024 financial guidance(6).